We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Breakthrough Molecular Detection Platform Delivers Best-In-Class Accuracy without Need for Target Amplification

By LabMedica International staff writers
Posted on 18 Oct 2023
Print article
Image: The CRISPR Cascade platform eliminates the need for target amplification (Photo courtesy of VedaBio)
Image: The CRISPR Cascade platform eliminates the need for target amplification (Photo courtesy of VedaBio)

A disruptive new platform that operates with a combination of unprecedented speed and accuracy promises to revolutionize molecular detection and emerge as a new gold standard tool to empower clinical decision-making.

VedaBio (San Diego, CA, USA) has harnessed the immense potential of CRISPR technology to create CRISPR Cascade, a game-changing platform that's the outcome of integrating engineering and biology. The CRISPR Cascade eliminates the requirement for target amplification yet offers the same level of accuracy as PCR tests, delivering analytical results in less than a minute. Unlike traditional DNA/RNA amplification methods like PCR, where increasing the complexity of the assay by multiplexing complicates things, CRISPR Cascade eliminates these constraints. It allows for extremely simple, highly multiplexed tests without sacrificing signal quality or encountering cross-reactivity. The platform offers a blend of high sensitivity, precision, and nearly immediate results, opening up a wide range of new possibilities.

One of the standout features of the CRISPR Cascade is its unprecedented speed and processing power, which facilitate almost instant results best-in-class accuracy. This is made possible by the use of two specific ribonucleoproteins (RNPs): the first, known as RNP1, identifies the target genetic sequence, while the second, RNP2, carries out an additional function, like signal amplification, for example. In contrast to existing DNA amplification methods like PCR, where combining multiple primers can reduce the assay's sensitivity and specificity, CRISPR Cascade can pool different RNP1s, allowing for massive multiplexing without any loss in signal-to-noise ratio (SNR) or cross-reactivity issues. This means that creating new tests or target applications becomes a matter of simple RNP1 adjustments. These modifications are compatible with various types of reporting mechanisms, including fluorescence and colorimetric methods. Thanks to its robust, room-temperature chemistry that is highly compatible with microfluidics, CRISPR Cascade enables almost immediate molecular detection along with significant multiplexing capabilities.

“With the CRISPR Cascade reaction, we have unlocked the true power of CRISPR with a platform that delivers near-instant molecular detection of highly multiplexed analytes with best-in-class accuracy, all without the need for target amplification,” said Anurup Ganguli, PhD, Co-Founder and Chief Executive Officer of VedaBio. “We believe it is poised to emerge as a future gold standard for molecular detection, empowering major advances across multiple applications including research and industrial tools, diagnostics and therapeutics.”

Related Links:

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Automated Staining Unit
RAL Stainer
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Viral DNA/RNA Isolation Kit
Mag-Bind Viral DNA/RNA Xpress Kit CE IVD

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.